Jan M, Sperling AS, Ebert BL. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021. doi:10.1038/s41571-021-00479-z
Cancer Program
Graubert A, Aguet F, Ravi A, Ardlie KG, Getz G. RNA-SeQC 2: Efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics. 2021. doi:10.1093/bioinformatics/btab135
Van Allen EM, Choueiri TK. Dissecting the immunogenomic biology of cancer for biomarker development. Nat Rev Clin Oncol. 2021;18(3):133-134. doi:10.1038/s41571-020-00461-1
He MX, Cuoco MS, Crowdis J, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021;27(3):426-433. doi:10.1038/s41591-021-01244-6
Richters A, Doyle SK, Freeman DB, et al. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2021;28(2):134-147.e14. doi:10.1016/j.chembiol.2020.10.001
Pikman Y, Tasian SK, Sulis ML, et al. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021. doi:10.1158/2159-8290.CD-20-0564
Fangusaro J, Bandopadhayay P. Advances in the classification and treatment of pediatric brain tumors. Curr Opin Pediatr. 2021;33(1):26-32. doi:10.1097/MOP.0000000000000975
Prensner JR, Enache OM, Luria V, et al. Noncanonical open reading frames encode functional proteins essential for cancer cell survival. Nat Biotechnol. 2021. doi:10.1038/s41587-020-00806-2
Lee MN, Meyerson M. Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells. Sci Immunol. 2021;6(55). doi:10.1126/sciimmunol.abf4001
Henley MJ, Doyle SK, Koehler AN. Nailing Down a Notoriously Elusive Cancer Target: Direct Inhibition of MYC by a Covalent Small Molecule. Cell Chem Biol. 2021;28(1):1-3. doi:10.1016/j.chembiol.2020.12.014